MedTrace Logo

An Assessment of the Occurrence of Hypothyroidism in Patients Treated With RAI for Hyperthyroidism.

NCT04663451 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2021-04-19

No results posted yet for this study

Summary

Low RAIU in patients with hyperthyroidism represents a common obstacle in the treatment with RAI. Therefore, a higher dose of RAI must be administered to cure hyperthyroidism in these patients. If we treat patients with thiamazole before starting RAI treatment, serum TSH will rise and result in an increase in iodine uptake by the thyroid gland. By doing so, the dose of RAI to be administered might be lowered to achieve similar therapeutic efficacy.

In the past, either calculated or fixed doses of 131I have been used to treat hyperthyroidism. The supposed advantage of a calculated dose compared to a fixed dose is the lowering of hypothyroidism frequency. However, various research papers have contradicted this statement.

Antithyroid drugs and RAI therapy have been widely used in the past, either in combination, or independent from one another. This has been done primarily in older patients, to reduce the risk of exacerbation of hyperthyroid symptoms after initiation of RAI.

The use of propylthiouracil has been shown to decrease the response rate after RAI due to radioprotective effects.

The use of methimazole and carbimazole did not have a negative effect on treatment failure, as long as the medication was discontinued various days before RAI administration. Although this statement is contested in other studies.

It is interesting to evaluate retrospective data of patients treated with RAI to evaluate prognostic factors of treatment respons and post RAI hypothyroidism.

Conditions

  • Nodule Solitary Thyroid
  • Toxic Multinodular Goiter
  • Radioactive Iodine-Induced Hypothyroidism

Interventions

RADIATION

radioacive iodine therapy

Hyperthyroid patients who have undergone radioactive iodine treatment to cure them from their hyperthyroidism.

Sponsors & Collaborators

  • Universitair Ziekenhuis Brussel

    lead OTHER

Principal Investigators

  • Corina Andreescu, Doctorate · Universitair Ziekenhuis Brussel

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-11
Primary Completion
2020-11-24
Completion
2021-05-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04663451 on ClinicalTrials.gov